Tolperisone-obl tab p / 50 mg of the film 30 pc

$5.02

Tolperisone-obl tab p / 50 mg of the film 30 pc

5 in stock

Quantity:

SKU: 2090483016 Categories: , , Tags: , ,

Description

Composition
Active substance:
1 tablet contains: tolperisone hydrochloride – 50 mg (for 50 mg dosage) or 150 mg (for a dosage of 150 mg) ;.
Excipients:
Citric acid, monohydrate lactose (milk sugar), giproloza (hydroxypropyl cellulose), crospovidone, stearic acid adjuvants for shell: Opadry II (85 Series) [polyvinyl alcohol, macrogol (polyethylene glycol), talc, titanium dioxide].
Description:
Tablets, film-coated white or almost white, lenticular, oblong shape with rounded ends, with Valium.
Product form:
Tablets, film-coated 50 mg and 150 mg.
5, 7, 10, 14, 15, 20, 30 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3 or 4, the contour of cellular packaging together with instructions for use placed in a pile of cardboard.
Contraindications
Male, age 18 years, hypersensitivity to the drug, pregnancy, lactation. Due to the presence of lactose, patients with lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.
Dosage
50 mg
Indications
Treatment pathologically increased tone and spasm of striated muscle due to organic neurological disorders (including loss of pyramidal tract, multiple sclerosis, stroke, myelopathy, encephalomyelitis).
increased tone and treatment of muscle cramps, muscle contractions that accompany diseases of the musculoskeletal system (spondylosis, spondylarthritis, arthrosis of large joints, cervical and lumbar pain syndromes).
Medical rehabilitation after surgical interventions in orthopedics and traumatology.
In combination therapy occlusive vascular disease (arteriosclerosis obliterans, diabetic angiopathy, thromboangiitis obliterans, Raynaud’s disease) and diseases resulting from disorders of innervation of blood vessels (acrocyanosis, intermittent angioneurotic disbaziya).
Interaction with other drugs
Tolperisone has an effect on the central nervous system, but does not cause sedation, can therefore be used in combination with sedatives, hypnotics, tranquillizers. It does not increase the effect of alcohol on the central nervous system. It increases the severity of the action niflumic acid, so their simultaneous use can reduce the dose of the latter. Medicines for general anesthesia and peripheral muscle relaxants, psychoactive drugs, clonidine enhance the effect.
Overdose
Symptoms: respiratory depression and cardiac activity, blood pressure reduction.
Treatment: symptomatic.
pharmachologic effect
Pharmacological group:
Muscle relaxants centrally acting.
Pharmacodynamics:
Muscle relaxant central mechanism of action. Has membrane stabilizing action, inhibits conduction of nerve impulses in primary afferent fibers and motoneurons, which leads to blocking of mono- and polysynaptic spinal reflexes. Probably mediates blocking release of mediators by inhibition Incoming Ca + 2 in synapses. Inhibits the conduction of excitation by reticulospinal path in the brainstem.
Regardless of the effect of central nervous system enhances the peripheral blood. In the development of this effect can play the role of a weak antispasmodic and antiadrenergic effect of tolperisone.
Pharmacokinetics:
After ingestion tolperisone well absorbed from the small intestine. Maximum plasma concentration is achieved after 30 min-1 h after administration, bioavailability due to first pass metabolism is expressed by around 20%. Tolperisone is extensively metabolized in the liver and kidneys. It excreted urine almost exclusively (99%) in the form of metabolites. The pharmacological activity is unknown metabolites.
Conditions of supply of pharmacies
On prescription.
side effects
Muscle weakness, headache, hypotension, nausea, gastralgia (generally tested at lower doses) rarely – hypersensitivity reactions (pruritus, erythema, urticaria, angioedema, bronchoconstriction, anaphylactic shock).
special instructions
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children !.
Dosing and Administration
Inside. Adult starting dose of 50 mg 2-3 times a day, gradually increasing to 150 mg 2-3 times a day.
The duration of treatment depends on the severity and nature of the disease.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Obolensky

There are no reviews yet.

Add your review